Table 2.
Univariate and Multivariate analysis for survival in higher risk MDS patients treated with decitabine
| Criterion | Univariate P value | Multivariate P value | HR | 95.0 % CI for HR |
|---|---|---|---|---|
| Hemoglobin (>80 g/L vs ≤80 g/L) | 0.010 | 0.026 | 2.023 | 1.177–4.112 |
| Platelet (>50 × 109/L vs ≤50 × 109/L) | 0.008 | 0.022 | 2.134 | 1.113–4.091 |
| Bone marrow blasts percentage (5–10/10–20/>20 %) | 0.010 | 0.041 | 1.522 | 1.017–2.277 |
| hENT1 expression (high vs low) | 0.027 | 0.031 | 2.363 | 1.174–4.757 |
| Age (>60 years vs ≤60 years) | 0.796 | – | – | – |
| Gender (male vs female) | 0.569 | – | – | – |
| Neutrophils (>1.0 × 109/L vs ≤1.0 × 109/L) | 0.212 | – | – | – |
| Karyotype (low/intermediate/high) | 0.318 | – | – | – |
| hENT2 expression (high vs low) | 0.201 | – | – | – |
| DCK expression (high vs low) | 0.203 | – | – | – |
| CDA expression (high vs low) | 0.411 | – | – | – |